DECAAF II - Efficacy of DE-MRI-Guided Ablation vs. Conventional Catheter Ablation of Atrial Fibrillation
DECAAF II Logo DECAAF II Logo

 

Efficacy of DE-MRI-Guided Fibrosis Ablation vs. Conventional Catheter Ablation of Atrial Fibrillation (DECAAF II)

DECAAF II is a research study investigating the treatment of atrial fibrillation (AF), a common heart rhythm disorder. Over the past 15 years, catheter ablation has been widely adopted as a treatment for atrial fibrillation. However, not all patients respond to the ablation procedure, and many revert back to the same irregular heartbeat that was present at the start. DECAAF II study is evaluating two types of catheter ablation to see which works best to stop the irregular heart beats.

What is ablation?

Catheter ablation treatements work like this: a physician guides a catheter to the specific area of the heart muscle, usually the upper chamber of the heart. Radiofrequency energy is directed through the catheter to specific heart cells. The intention is that the energy from the catheter will stop the irregular conductions and restore normal heart rhythm.

The primary objective of the study is to examine the efficacy of targeting atrial fibrosis tissue during
an ablation procedure in treating persistent AF

The DECAAF II study evaluates two different types of catheter ablation treatments. One group of study participants will receive conventional catheter ablation treatment, and the other will receive catheter ablation guided by a specific type of imaging process that shows area of fibrosis in the heart. The catheter will then target these areas of fibrosis. The researchers will evaluate which treatment works best to prevent recurrence of atrial fibrillation.

 

 

Where will the study take place?

Several hospitals from across the globe will participate in this study. Participating countries and sites can be seen here. Link to Clinical Centers.   We will update this list as sites join.

Where is the lead site for this study?

Dr. Nassir Marrouche is a cardiologist at the University of Utah and is the lead investigator of the DECAAF II study.

 

Study Supporters

The study is supported by: Siemens, St. Jude Medical, Biosense Webster, Boston Scientific, Medtronic (European sites only), and General Electric (GE) Healthcare.

 

 

(In accordance with the Americans with Disabilities Act, the information in this site is available in alternate formats upon request.)